Drugs / Decitabine and Cedazuridine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05564390 | Jun 2024 → May 2029 expected | acute myeloid leukemia with multilineage dysplasia, myelodysplastic syndrome | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Decitabine and Cedazuridine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05564390 ↗ |
| Route | Oral | “Given PO” NCT05564390 ↗ |